Report Highlights

U.S. Immunity Boosting Foods: Market Overview

The U.S. immunity boosting food products market was valued at USD 21.4 billion in 2024 and is forecast to reach USD 36.8 billion by 2032, growing at a 7.0% CAGR. Demand spans fortified beverages, probiotic yogurts, gummies, elderberry syrups and functional bars. Supplements and conventional foods share a regulatory boundary defined by the Dietary Supplement Health and Education Act of 1994. Private firms have led product innovation, while government shapes the market mainly through labeling rules.

Market structure is split between large multinationals and mid-sized brands. Nestlé Health Science and Danone North America compete in probiotics and functional beverages, while Church & Dwight's Emergen-C dominates vitamin C effervescent formats. Government funds research through the NIH Office of Dietary Supplements but does not set product demand. The FTC and FDA's 2020 warning letters against COVID-19 immunity claims permanently shifted marketing toward evidence-backed language.

Policy-Driven Growth in U.S. Immunity Boosting Foods

The Dietary Supplement Health and Education Act of 1994 permits structure/function claims such as "supports immune health" without premarket FDA approval, provided manufacturers notify FDA within 30 days of first marketing under 21 CFR 101.93. This pathway lets brands launch fortified products within weeks, converting regulatory permissiveness into rapid SKU growth. The FDA's final rule on "healthy" nutrient content claims, published in December 2024 with manufacturer compliance due by February 25, 2028, links the label to defined nutrient thresholds and enables fortified products to qualify.

The Make America Healthy Again Commission, established by Executive Order on February 13, 2025, has prioritized nutrient-dense food and removal of synthetic colorants. Its May 2025 assessment pushed food processors toward naturally sourced vitamin C, zinc and probiotic ingredients. Both HHS and USDA coordinate implementation. Retail buyers respond to these signals by expanding functional shelf space, translating political priority into distribution gains within twelve to eighteen months of reformulation.

Regulatory Barriers and Compliance Costs

Preventive controls under 21 CFR Part 117, enforced by the FDA Human Foods Program, require written food safety plans and a qualified individual at each facility, a fixed overhead that smaller processors often struggle to absorb. The Food Traceability Rule under Section 204 of FSMA requires Key Data Elements for listed foods, and FDA extended its compliance date from January 20, 2026 to July 20, 2028. Third-party GFSI-benchmarked certification adds audit fees that emerging brands cite as the first barrier to national retail listing.

Novel ingredients face the sharpest delays. Under Section 413 of the FD&C Act, any new dietary ingredient not marketed before October 15, 1994 requires a notification filed at least 75 days before marketing, stalling novel postbiotic strains and botanical extracts. HHS directed FDA in March 2025 to close the self-affirmed GRAS pathway under 21 CFR 170.36, which has enabled rapid ingredient adoption. California's Proposition 65 adds litigation exposure through 60-day notices targeting lead in plant-based powders.

Policy-Created Opportunities in the U.S.

The USDA Specialty Crop Block Grant Program, funded with $72.9 million in mandatory money each year, supports state-administered projects that develop value-added fruit and vegetable ingredients. Eligible processors can apply through state departments of agriculture to build vitamin C and polyphenol-rich ingredient lines, creating domestic supply that reduces reliance on imported concentrates. Brands formulating immunity claims gain a secure, traceable input base that satisfies FSMA Section 204 requirements.

The "healthy" claim rule, with manufacturer compliance due February 25, 2028, gives fortified products meeting nutrient-content thresholds a federally recognized label that retailers will use as a shelf differentiator. USDA's National School Lunch Program procurement under 7 CFR 210.21 and the USDA Foods catalog provide a route for fortified dairy and fruit-based products into school distribution, where Buy American provisions favor domestically manufactured ingredients.

Market at a Glance

Leading Market Participants

• Nestlé Health Science
• Danone North America
• Kerry Group
• Church & Dwight
• Herbalife Nutrition
• The Bountiful Company
• Unilever
• Hain Celestial Group
• Glanbia
• Nature's Sunshine Products

Regulatory and Policy Environment

The primary legal framework is the Federal Food, Drug, and Cosmetic Act of 1938, as amended by the Dietary Supplement Health and Education Act of 1994 and the FDA Food Safety Modernization Act of 2011. The FDA Human Foods Program, created in October 2024, administers labeling under 21 CFR Part 101. The Federal Trade Commission enforces advertising substantiation under Section 5 of the FTC Act. Key compliance requirements include Supplement Facts panel formatting, 30-day structure/function notifications, and 75-day new dietary ingredient filings.

Upcoming changes will reshape compliance. FDA's proposed front-of-package nutrition labeling rule, published in January 2025, would add standardized nutrient information to packaged foods. The healthy claim compliance date arrives February 25, 2028, and FSMA Section 204 traceability obligations follow on July 20, 2028. Compared with peers, the U.S. framework is more permissive than the European Union's Regulation (EC) No 1924/2006, which limits health claims to EFSA-authorized wording, and Health Canada's Natural Health Products Regulations, which require a product license and Natural Product Number before sale.

Long-Term Policy Outlook for U.S. Immunity Boosting Foods

By 2032 the most consequential change will be the closure of self-affirmed GRAS, following HHS's March 2025 directive, which will require FDA notification for every ingredient and extend reformulation timelines by months. Texas Senate Bill 25, signed in 2025, requires warning labels for listed ingredients beginning in 2027, while California's Assembly Bill 418 bans Red No. 3 from January 2027. These state measures extend ingredient restrictions into immunity products sold nationwide.

Claim governance will also tighten. The FTC's continued scrutiny of "immune support" language, combined with the front-of-package rule, will push the market toward substantiated, dose-specified claims. Brands that generate clinical dosing data before the 2028 compliance dates will hold claim rights as enforcement matures, while unsubstantiated elderberry and vitamin C positioning loses retail visibility. Retailers will also demand documented substantiation files from suppliers, turning compliance records into a commercial requirement for listing.